The EDC3 Knockout A-549 Polyclonal Cells comprise a heterogeneous population of CRISPR/Cas9-edited A-549 cells carrying targeted disruptions in the EDC3 gene, producing a loss-of-function model for the mRNA decapping activator. This polyclonal knockout product provides a versatile tool for analyzing post-transcriptional gene regulation without isolating individual clones, allowing researchers to study EDC3-dependent processes in bulk cell populations.
The host cell line, A-549, is an adherent epithelial-like cell line derived from human lung adenocarcinoma, serving as a widely used model for non-small cell lung cancer. These cells exhibit alveolar basal epithelial characteristics and are commonly employed for studying cancer biology, drug responses, and gene expression programs relevant to lung tumorigenesis.
EDC3 functions as a scaffolding protein that enhances the decapping of messenger RNA, a critical step in 5′-to-3′ mRNA decay. It interacts directly with the decapping enzyme subunits DCP1A and DCP2, and with additional P-body components including EDC4, DDX6, LSM1, PATL1, and the exonuclease XRN1. Through these interactions, EDC3 promotes the assembly of processing bodies (P-bodies) and facilitates the degradation of specific short-lived transcripts downstream of stress signals and the mTOR signaling pathway. Consequently, EDC3 regulates mRNA stability and influences the expression of genes involved in cell growth and stress responses.
In the A-549 lung adenocarcinoma background, disruption of EDC3 is particularly significant for investigating how aberrant mRNA decay contributes to cancer cell behavior. The knockout model enables functional interrogation of EDC3-mediated post-transcriptional regulation in a clinically relevant lung cancer context, potentially revealing links between mRNA turnover pathways and oncogenic processes such as proliferation, survival, and metastasis.
This polyclonal knockout cell population is suitable for a variety of experimental approaches, including western blotting to confirm EDC3 protein loss, RT-qPCR and actinomycin D chase assays to measure changes in mRNA half-life, RNA sequencing to identify EDC3-regulated transcripts, and immunofluorescence to visualize alterations in P-body dynamics using markers like DCP1A. Co-immunoprecipitation studies can assess the integrity of the decapping complex in the absence of EDC3. For further technical details, please contact Ascent Research.
